Clinical trial NCT06675617: EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
Official title: A Clinical Study to Evaluate the Effectiveness and Safety of the Allay® Aortic Stent as Adjunctive Endovascular Treatment of Type B Aortic Dissection in Patients Eligible for Thoracic Endovascular Repair With Stent Grafts
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Type B Aortic Dissection
Keywords: TBAD
Allay
aortic
dissection
type B
Lead sponsor: Intressa Vascular SA
Sponsor class: INDUSTRY
First posted: 2024-11-05
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This clinical trial is a prospective, multicenter, open label study designed to evaluate the effectiveness and the safety of the Allay® Aortic Stent as adjunctive endovascular treatment of Type B aortic dissection in patients eligible for thoracic endovascular aortic repair with stent grafts.

Detailed description: Thoracic endovascular repair (TEVAR) with stent grafts is recommended for patients with acute complicated or high-risk type B aortic dissection (TBAD) as part of standard of care per current medical guidelines. Although the benefits of TEVAR with stent grafts are well established, there remains a significant risk of late complications, including aortic growth requiring reinterventions, or progression and/or rupture.

In the present clinical investigation, the investigational procedure of adjunctive thoracic stent graft extension with the Allay® Aortic Stent will consist of the placement of a CE-marked Thoracic Stent Graft in the descending thoracic aorta (proximal to the celiac trunk) followed by the implantation of the Allay® Aortic Stent as adjunctive treatment of TBAD.

The study objective is to demonstrate that the Allay® Aortic Stent, used as adjunctive endovascular treatment of Type B aortic dissection in patients eligible for thoracic endovascular aortic repair with stent grafts, results in a low rate of aortic growth requiring secondary reintervention, including open conversion, or aortic rupture in the treated abdominal segment at 12 months. The study will also allow to evaluate the incidence of Major Adverse Events (MAE) following TEVAR, at 30 days post-implantation of the Allay® Aortic Stent.

Based on available data on similar devices, the objective performance goal is set to an expected proportion of 85% freedom from aortic growth requiring secondary reintervention or aortic rupture of the abdominal segment at 12 months.

Eligibility criteria: Inclusion Criteria:

* Have a type B aortic dissection extending to the celiac trunk or beyond
* Are eligible for thoracic endovascular treatment with stent grafts as per local guidelines, and physician's decision
* Have been elected for treatment with commercially available stent graft as per their IFU within 90 days of dissection symptoms onset

Exclusion Criteria:

* General Exclusion Criteria:

  * Age \< 18 years
  * Pregnant, breast-feeding or planning on becoming pregnant during the entire duration of the study
  * Unable to provide written informed consent
  * Unable or unwilling to comply with the requirements of the study protocol
  * Taking part already in an investigational device or drug study that could interfere with the outcomes being studied
  * Active drug addiction or known history of drug abuse within one year of treatment
* Medical Exclusion Criteria:

  * Aortic rupture, free or contained including haemothorax, increasing periaortic hematoma, or mediastinal hematoma
  * Aortic fistula
  * Suspicion of bowel necrosis or irreversible visceral ischemia
  * Stage 5 chronic kidney disease
  * Life expectancy of less than 2 years due to any other medical condition than the dissection to be treated
  * Active malignancy
  * Known sensitivities or allergies to the device materials (including cobalt, chromium, nickel)
  * Known sensitivities or allergies to contrast materials that cannot be pre-medicated
  * Mycotic aortic aneurysm or active systemic infection that may place the patient at increased risk of endovascular infection
  * American Society of Anaesthesiologists (ASA) class V (moribund patient not expected to live 24 hours with or without operation)
  * Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's, Loeys-Dietz or Ehlers-Danlos syndrome)
  * Uncorrectable coagulopathy, bleeding diathesis or refusal of blood transfusion
  * Any major cardiovascular or cerebrovascular ischemic event, including myocardial infarction or stroke, or treatment of such event, within 90 days prior to enrolment
  * Any aortic-related interventional or surgical procedure within 30 days prior to enrolment
  * Any planned aortic-related interventional or surgical procedure within 30 days after the study procedure
* Anatomical Exclusion Criteria:

  * Aneurysmal dilatation of the false lumen defined as maximum transaortic diameter \>55 mm in women or \>60 mm in men in the thoraco-abdominal segment or \>50 mm in women or \>55 mm in men in the abdominal segment, measured inner-wall to inner-wall;
  * Inadequate proximal landing zone for the stent graft, such zone being \<20 mm long
  * Inadequate proximal landing zone geometry for the Allay® Aortic Stent (e.g. aortic kink)
  * Planned implantation of a stent graft with a distal diameter \>38 mm or \<20 mm
  * Aorta or iliac anatomy not allowing the advancement of the delivery system
  * Subject in whom the thoracic stent graft is either 1) not implanted in its intended position and/or 2) leads to any serious device complication, and/or who has 3) persistent static obstruction of the visceral or both renal arteries, prior to Allay® Aortic Stent implantation, will not be implanted with the Allay® Aortic Stent and will be withdrawn from the study

Primary outcomes:
measure: Freedom from aortic growth requiring secondary reintervention, including open conversion, or aortic rupture in the region treated by the Allay® Aortic Stent at 12 months
timeFrame: 12 months
Secondary outcomes:
measure: Percentage of Participants with Successful Technical Performance of the Allay® Aortic Stent Implantation
timeFrame: At index procedure
measure: Incidence of Major Adverse Events (MAE) within 30 Days After Allay® Aortic Stent Implantation
timeFrame: 30 days
measure: Freedom from all-cause mortality;
timeFrame: Immediately at discharge and subsequent follow-up visits, at 30 days, 12, 24, 36, 48 and 60 months
measure: Freedom from Dissection-Related Mortality
timeFrame: Immediately at discharge and subsequent follow-up visits at 30 days, 12, 24, 36, 48, and 60 months.
measure: Freedom from Readmission (Post-Discharge)
timeFrame: Subsequent follow-up visits at 30 days, 12, 24, 36, 48, and 60 months.
measure: Freedom from Aorta-Related Reintervention
timeFrame: Immediately at discharge and subsequent follow-up visits at 30 days, 12, 24, 36, 48, and 60 months.
measure: Freedom from Open Conversion
timeFrame: Immediately at discharge and subsequent follow-up visits at 30 days, 12, 24, 36, 48, and 60 months.
measure: Freedom from New Ischemia
timeFrame: Immediately at discharge and subsequent follow-up visits at 30 days, 12, 24, 36, 48, and 60 months.
measure: Freedom from Reintervention Related to Side Branches
timeFrame: Immediately at discharge and subsequent follow-up visits at 30 days, 12, 24, 36, 48, and 60 months.
measure: Aortic rupture
timeFrame: Assessed at discharge or not later than 30 days from index procedure, and then compared to pre-operative CT scan
measure: Percentage of Participants with Patent Major Aortic Branches Post-Allay® Aortic Stent Implantation
timeFrame: Assessed at discharge (or within 30 days from the index procedure) and compared to the pre-operative CT scan.
measure: Percentage of Participants with Patent Major Descending Aortic Branches Covered by the Allay® Aortic Stent
timeFrame: Assessed at discharge (or within 30 days from the index procedure) and compared to the pre-operative CT scan.
measure: Percentage of Participants with Device Deficiencies Detected by CT Imaging Post-Allay® Aortic Stent Implantation
timeFrame: Assessed at discharge (or within 30 days from the index procedure) and compared to the pre-operative CT scan.
measure: Aortic growth
timeFrame: Assessed at 12, 24, 36, 48 and 60 months, then compared to first post-operative CT scan done at discharge and not later than 30 days from index procedure
measure: Aortic Rupture
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan done at discharge.
measure: New Dissection or Extension of Dissection
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan.
measure: Percentage of Participants with Fistula Formation Detected on Follow-Up CT Imaging
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan.
measure: Change in True Lumen, False Lumen, and Transaortic Diameters
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan.
measure: Percentage of Participants with Maintained Patency in Major Aortic Branches on Follow-Up Imaging
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan.
measure: Percentage of Participants with Maintained Patency in Major Descending Aortic Branches Covered by the Allay® Aortic Stent on Follow-Up Imaging
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan.
measure: Percentage of Participants with Maintained False Lumen Perfusion and Patency in All Treated Segments on Follow-Up Imaging
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan.
measure: Percentage of Participants with Device Deficiencies on Follow-Up Imaging
timeFrame: Assessed at 12, 24, 36, 48, and 60 months, compared to the first post-operative CT scan.
Other outcomes:
Locations:
city: Genk
country: Belgium
facility: Ziekenhuis Oost-Limburg
city: Leuven
country: Belgium
facility: UZ Leuven
city: Liège
country: Belgium
facility: CHU Liège
city: Sofia
country: Bulgaria
facility: Acibadem City Clinic University Hospital and Cardiovascular Center
city: Paris
country: France
facility: Hopital Européen Georges Pompidou AP-HP
city: Kiel
country: Germany
facility: Universitätsklinikum Schleswig-Holstein
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig AöR
city: Münster
country: Germany
facility: University Hospital of Münster
city: Belgrad
country: Serbia
facility: University Clinical Centre of Serbia
city: Tashkent
country: Uzbekistan
facility: Republican Research Centre of Emergency Medicine
Study officials:
affiliation: Medical University of Vienna
name: Wolf-Hans Eilenberg, MD, PhD, FEBVS
role: PRINCIPAL_INVESTIGATOR
References: